AstraZeneca PLC (AZN) Oncology Sales Hit $12B in H1 2025

We recently published 11 Best Cancer Stocks to Buy Right Now. AstraZeneca PLC stands third among them.

AstraZeneca PLC (NASDAQ:AZN), headquartered in Cambridge, England, is a leading global biopharmaceutical company with a major role in the oncology sector. Its cancer portfolio covers lung, breast, gastric, and gastroesophageal cancers, with key drugs including Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu.

In the first half of 2025, AstraZeneca PLC (NASDAQ:AZN)’s oncology sales reached nearly $12 billion, up 16% year-over-year, driven by strong demand across its core therapies. New launches such as Truqap for breast cancer and Datroway for EGFR-mutated non-small cell lung cancer have also expanded its market presence, solidifying its position among the best cancer stocks to watch.

Regulatory and clinical progress further reinforced momentum. The FDA granted Priority Review for Imfinzi in early-stage and locally advanced gastric and gastroesophageal cancers, with a decision expected in late 2025. Positive Phase III results were reported for Enhertu (DESTINY-Breast09), Imfinzi (MATTERHORN), and camizestrant (SERENA-6), strengthening the business’s late-stage pipeline. Enhertu also showed the ability to delay breast cancer progression by 14 months, signaling potential label expansion.

Strategically, AstraZeneca PLC (NASDAQ:AZN) streamlined its pipeline by discontinuing early CAR-T and TCR-T candidates for solid tumors, redirecting investment toward high-potential immuno-oncology and targeted therapies.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.